Literature DB >> 17682988

Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.

Shyam Sundar1, J Chakravarty, V K Rai, N Agrawal, S P Singh, V Chauhan, Henry W Murray.   

Abstract

BACKGROUND: For patients with Indian visceral leishmaniasis, amphotericin B deoxycholate is usually given as 15 alternate-day infusions of 1 mg/kg over 30 days (total dose, 15 mg/kg); daily treatment with 1 mg/kg for 20 days (total dose, 20 mg/kg) is also used. This study was done to address the unsettled therapeutic questions of administration schedule (alternate-day vs. daily administration) and dose (1 vs. 0.75 mg/kg) and to determine whether the duration of amphotericin B treatment in Bihar, India, can be shortened to 15 days.
METHODS: To compare alternate-day versus daily administration and 1-mg/kg versus 0.75-mg/kg doses and to determine whether the duration of treatment could be abbreviated, Indian subjects randomly received 15 infusions of 1 mg/kg (group A; 245 patients) or 0.75 mg/kg (group B; 244 patients) on alternate days or 1 mg/kg (group C; 500 patients) or 0.75 mg/kg (group D; 496 patients) daily. Noninferiority testing compared 6-month cure rates using a 5% margin.
RESULTS: Overall, 1439 of the 1485 subjects completed treatment and responded. Treatment interruptions (nephrotoxicity) but not infusion-associated reactions or study removals were more common with daily administration. Final cure rates at 6 months were similar: group A, 234 patients (96%; 95% confidence interval [CI], 92%-98%); group B, 225 patients (92%; 95% CI, 88%-95%); group C, 483 patients (97%; 95% CI, 95%-98%); and group D, 476 patients (96%; 95% CI, 94%-97%; P>.05).
CONCLUSIONS: Provided that the serum creatinine level is repeated once, daily treatment with amphotericin B, 0.75 mg/kg for 15 days (total dose, 11.25 mg/kg), is efficient and effective for visceral leishmaniasis in India. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00310505.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17682988     DOI: 10.1086/520665

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  25 in total

1.  Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India.

Authors:  Shyam Sundar; Prabhat K Sinha; Susan A Dixon; Renata Buckley; Ann K Miller; Khadeeja Mohamed; Mahir Al-Banna
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh.

Authors:  Mahmudur Rahman; Be-Nazir Ahmed; M Abul Faiz; M Zafor Ullah Chowdhury; Quazi Tarikul Islam; Rahman Sayeedur; M Ridwanur Rahman; Moazzem Hossain; Abdul Mannan Bangali; Ziauddin Ahmad; M Nazrul Islam; C G Nicholas Mascie-Taylor; Jonathan Berman; Byron Arana
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

3.  Cross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophages.

Authors:  Tatiana R de Moura; Micheli Luize Barbosa Santos; Juciene M Braz; Luis Felipe V C Santos; Matheus T Aragão; Fabricia A de Oliveira; Priscila L Santos; Ângela Maria da Silva; Amélia Ribeiro de Jesus; Roque P de Almeida
Journal:  Parasitol Res       Date:  2016-02       Impact factor: 2.289

4.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

Review 5.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-11-17

6.  Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance.

Authors:  Rati Tandon; Sharat Chandra; Rajendra Kumar Baharia; Sanchita Das; Pragya Misra; Awanish Kumar; Mohammad Imran Siddiqi; Shyam Sundar; Anuradha Dube
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

7.  A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.

Authors:  Krishna Pandey; Biplab Pal; Niyamat Ali Siddiqui; Chandra Shekhar Lal; Vahab Ali; Sanjiva Bimal; Ashish Kumar; Neena Verma; Vidya Nand Rabi Das; Shubhankar Kumar Singh; Roshan Kamal Topno; Pradeep Das
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

8.  Formation of two different types of ion channels by amphotericin B in human erythrocyte membranes.

Authors:  Eneida A Romero; Elizabeth Valdivieso; B Eleazar Cohen
Journal:  J Membr Biol       Date:  2009-07-23       Impact factor: 1.843

Review 9.  Drug resistance in visceral leishmaniasis.

Authors:  Helena C Maltezou
Journal:  J Biomed Biotechnol       Date:  2009-11-01

10.  Chemical and environmental vector control as a contribution to the elimination of visceral leishmaniasis on the Indian subcontinent: cluster randomized controlled trials in Bangladesh, India and Nepal.

Authors:  Anand B Joshi; Murari L Das; Shireen Akhter; Rajib Chowdhury; Dinesh Mondal; Vijay Kumar; Pradeep Das; Axel Kroeger; Marleen Boelaert; Max Petzold
Journal:  BMC Med       Date:  2009-10-05       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.